Table 1 Demographics of glioma patients admitted in our hospital from 2015 to 2022
WHO grade | Age range | Mean (yrs ± SD) | Male n (%) | Female n (%) | Ratio (M:F) | Total n (%) | |
|---|---|---|---|---|---|---|---|
All gliomas | 1–4 | 3 to 75 yrs | 41.7 ± 18.2 | 81 (56.3%) | 63 (43.8%) | 1.3:1 | 144 |
Astrocytoma | 1 | 21 to 32 yrs | 26.5 ± 7.8 | 0 (0%) | 2 (100%) | – | 2 (1.4%) |
Astrocytoma | 2 | 7 to 69 yrs | 40.7 ± 16.4 | 24 (52.2%) | 22 (47.8%) | 1.1:1 | 46 (31.9%) |
Astrocytoma | 3 | 17 to 75 yrs | 46.2 ± 14.6 | 25 (59.5%) | 17 (33.3%) | 1.5:1 | 42 (29.2%) |
Astrocytoma | 4 | 3 to 73 yrs | 52.2 ± 21.1 | 11 (55%) | 9 (45%) | 1.2:1 | 20 (13.9%) |
Diffuse astrocytoma | 2 | 22 to 69 yrs | 39.2 ± 12.5 | 7 (63.6%) | 4 (36.4%) | 1.8:1 | 11 (7.4%) |
Ganglioglioma | 2 | 18 to 66 yrs | 42 ± 33.9 | 0 (0%) | 2 (100%) | – | 2 (1.4%) |
Oligoastrocytoma | 2 | 39 yrs | 39 ± 0.0 | 1 (66.7%) | 0 (0%) | – | 1 (0.7%) |
3 | 52 to 66 yrs | 59 ± 9.9 | 1 (50%) | 1 (50%) | 1:1 | 2 (1.4%) | |
Oligodendroglioma | 3 | 27 to 65 yrs | 45.8 ± 14.5 | 5 (83.3%) | 1 (16.7%) | 5:1 | 6 (4.2%) |
Pilocytic astrocytoma | 1 | 3 to 25 yrs | 10.8 ± 6.8 | 6 (60%) | 4 (40%) | 1.5:1 | 10 (6.9%) |
Pleomorphic xanthroastrocytoma | 3 | 20 to 40 yrs | 30 ± 14.1 | 1 (50%) | 1 (50%) | 1:1 | 2 (1.4%) |